Display options
Cite
Szatkowski W, Blecharz P, Mituś JW, et al. Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer. Hered Cancer Clin Pract. 2016;14:4doi: 10.1186/s13053-015-0041-2.
Szatkowski, W., Blecharz, P., Mituś, J. W., Jasiówka, M., Łuczyńska, E., Jakubowicz, J., & Byrski, T. (2016). Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer. Hereditary cancer in clinical practice, 144. https://doi.org/10.1186/s13053-015-0041-2
Szatkowski, Wiktor, et al. "Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer." Hereditary cancer in clinical practice vol. 14 (2016): 4. doi: https://doi.org/10.1186/s13053-015-0041-2
Szatkowski W, Blecharz P, Mituś JW, Jasiówka M, Łuczyńska E, Jakubowicz J, Byrski T. Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer. Hered Cancer Clin Pract. 2016 Jan 23;14:4. doi: 10.1186/s13053-015-0041-2. eCollection 2016. PMID: 26807161; PMCID: PMC4724399.
Copy Download .nbib Format: NLM
Share it on

Hered Cancer Clin Pract. 2016 Jan 23;14:4. doi: 10.1186/s13053-015-0041-2. eCollection 2016.

Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer.

Hereditary cancer in clinical practice

Wiktor Szatkowski, Paweł Blecharz, Jerzy W Mituś, Marek Jasiówka, Elżbieta Łuczyńska, Jerzy Jakubowicz, Tomasz Byrski

Affiliations

  1. Department of Gynaecological Oncology, Centre of Oncology, Maria Sk?odowska-Curie Memorial Institute, Kraków Branch, ul. Garncarska 11, 31-115 Kraków, Poland.
  2. Department of Surgical Oncology, Centre of Oncology, Maria Sk?odowska-Curie Memorial Institute, Kraków Branch, ul. Garncarska 11, 31-115 Kraków, Poland ; Department of Anatomy, Collegium Medicum, Jagiellonian University, ul. Kopernika 12, 31-034 Kraków, Poland.
  3. Department of Medical Oncology, Centre of Oncology, Maria Sk?odowska-Curie Memorial Institute, Kraków Branch, ul. Garncarska 11, 31-115 Kraków, Poland.
  4. Department of Radiology, Centre of Oncology, Maria Sk?odowska-Curie Memorial Institute, Kraków Branch, ul. Garncarska 11, 31-115 Kraków, Poland.
  5. Department of Radiotherapy, Centre of Oncology, Maria Sk?odowska-Curie Memorial Institute, Kraków Branch, ul. Garncarska 11, 31-115 Kraków, Poland.
  6. Department of Genetics and Pathology, International Hereditary Cancer Center and Clinic of Oncology Pomeranian Medical University, Szczecin, ul. Po?abska 4, 70-115 Szczecin, Poland.

PMID: 26807161 PMCID: PMC4724399 DOI: 10.1186/s13053-015-0041-2

Abstract

BACKGROUND: Treatment outcomes appear to be better for ovarian cancer (OC) patients carrying the BRCA1/2 germline mutation than for patients with sporadic OC. However, most published data are for North American, British and Jewish populations. There have been very few studies on treatment outcomes in Central and Eastern European patients with OC. The aim of this study was to analyse prognostic factors in Polish patients with BRCA1-dependent OC (BRCA1-OC).

METHODS: The records of patients with OC treated with surgery and chemotherapy at the Centre of Oncology in Kraków, Poland, between 2004 and 2009 were reviewed. Based on family history, a group of 249 consecutive patients fulfilling the criteria for risk of hereditary OC were selected and tested for the germline BRCA1 mutation. Response to combination therapy (surgery and chemotherapy) in the BRCA1-OC group was assessed based on clinical examination, imaging and serum CA125.

RESULTS: Germline BRCA1 mutations were detected in 69 of the 249 patients, but three of these patients failed to complete the study. Finally, 66 patients with BRCA1-OC were included in the study group. The median age of the study patients was 49.5 years. All had undergone primary or interval cytoreductive surgery and chemotherapy. Progression occurred in 48 (72.7 %) of the 66 patients and median time to progression was 20 months. The 5-year overall survival rate in was 43.9 % and median survival time was 32.3 months. On multivariate analysis, the endometrial subtype of OC and serum CA125 < 12.5 U/ml at the end of treatment were independent, positive prognostic factors for 5-year overall survival.

CONCLUSION: Prognostic factors for favourable treatment outcomes in Polish patients with BRCA1-OC do not appear to differ from those in patients with sporadic OC. The incidence of the endometrial subtype of OC was relatively high (34.9 %) among women in the study. This was unexpected and has not been reported previously. This subtype of OC was an independent prognostic factor for favourable treatment outcomes.

Keywords: BRCA1; Ovarian cancer; Prognostic factors

References

  1. Gynecol Oncol. 1999 May;73(2):242-6 - PubMed
  2. J Clin Oncol. 2008 Dec 1;26(34):5530-6 - PubMed
  3. Cancer. 2005 Sep 1;104(5):1004-12 - PubMed
  4. J Clin Oncol. 2008 Jan 1;26(1):20-5 - PubMed
  5. Gynecol Oncol. 2012 Feb;124(2):216-20 - PubMed
  6. Eur J Cancer. 2010 May;46(8):1359-64 - PubMed
  7. JAMA. 2000 May 3;283(17):2260-5 - PubMed
  8. Gynecol Oncol. 2011 May 1;121(2):358-63 - PubMed
  9. Br J Cancer. 1977 Jan;35(1):1-39 - PubMed
  10. Clin Cancer Res. 2002 May;8(5):1196-202 - PubMed
  11. Cancer. 2012 Aug 1;118(15):3703-9 - PubMed
  12. Gynecol Oncol. 1987 Mar;26(3):284-9 - PubMed
  13. Breast Cancer Res. 2012 Jul 20;14(4):R110 - PubMed
  14. Ann Oncol. 2013 Aug;24(8):2036-42 - PubMed
  15. Eur J Surg Oncol. 2001 Apr;27(3):278-81 - PubMed
  16. Gynecol Oncol. 2003 Aug;90(2):390-6 - PubMed
  17. N Engl J Med. 1996 Nov 7;335(19):1413-6 - PubMed
  18. Cancer. 2003 May 1;97(9):2187-95 - PubMed
  19. Ann Oncol. 2011 May;22(5):1127-32 - PubMed
  20. Gynecol Oncol. 2012 Jun;125(3):677-82 - PubMed
  21. JAMA. 2012 Jan 25;307(4):382-90 - PubMed
  22. Gynecol Oncol. 2008 May;109(2):187-93 - PubMed
  23. Anticancer Res. 1997 Jul-Aug;17(4B):2945-7 - PubMed
  24. Cancer Res. 1999 Feb 15;59(4):868-71 - PubMed
  25. BMC Cancer. 2005 Oct 17;5:134 - PubMed
  26. Gynecol Oncol. 2001 Jun;81(3):398-403 - PubMed
  27. Br J Cancer. 2004 Feb 23;90(4):810-4 - PubMed

Publication Types